AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24701571 — intervention group
Group type: COMPARATOR
Intervention: Isobaric levobupivacaine
Number of subjects: 60
Study 22012130 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose recombinant human erythropoietin (rHuEPO) 40,000 units
Number of subjects: 88
Study 22012130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 21118924 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly SP
Number of subjects: 1320
Study 21118924 — intervention group
Group type: EXPERIMENTAL
Intervention: AZI-SP (monthly SP and two doses of azithromycin)
Number of subjects: 1320
Study 21118924 — intervention group
Group type: COMPARATOR
Intervention: Controls (sulfadoxine‐pyrimethamine twice)
Number of subjects: 1320
Study 17541591 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 30 mg/m2 i.v.
Number of subjects: 48
Study 17541591 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine 80 mg/m2 oral
Number of subjects: 48
Study 17541591 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and i.v. forms
Number of subjects: 48
Study 15821961 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐SSP
Number of subjects: 66
Study 15821961 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin‐section MR imaging
Number of subjects: 66
Study 15821961 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaxial SPECT display
Number of subjects: 66
Study 15821961 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion MR imaging
Number of subjects: 66
Study 11956002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide treatment
Number of subjects: 100
Study 11956002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9585289 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine without epinephrine (Group A)
Number of subjects: 80
Study 9585289 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus 0.2 mg of epinephrine (Group B)
Number of subjects: 80
Study 9585289 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus 0.4 mg of epinephrine (Group C)
Number of subjects: 80
Study 9585289 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus 0.6 mg of epinephrine (Group D)
Number of subjects: 80
Study 7712756 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (0.1 mg/kg/day)
Number of subjects: 18
Study 7712756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2667704 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine (52 mg/nasal cavity)
Number of subjects: 12
Study 2667704 — intervention group
Group type: COMPARATOR
Intervention: Placebo (topically applied)
Number of subjects: 12
Study 827772 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (3 mg total dose, intravenously)
Number of subjects: 23
Study 827772 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.25 N saline, intravenously)
Number of subjects: 23
Study 31059560 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 primer pairs selected for polymorphism validation
Number of subjects: 96
Study 31059560 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphic EST-SSR markers
Number of subjects: 96
Study 31059560 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic diversity analysis
Number of subjects: 96
Study 31059560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-transferability of markers
Number of subjects: 96
Study 28088688 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX and bevacizumab (arm A)
Number of subjects: 79
Study 28088688 — intervention group
Group type: COMPARATOR
Intervention: CAPOX alone (arm B)
Number of subjects: 79
Study 26631990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary device
Number of subjects: 0
Study 26631990 — intervention group
Group type: COMPARATOR
Intervention: Extramedullary hip screw
Number of subjects: 0
Study 23749226 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (100 kVp, 370 mgI/kg over 15 s)
Number of subjects: 98
Study 23749226 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (100 kVp, 296 mgI/kg over 10 s)
Number of subjects: 98
Study 23749226 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C (80 kVp, 296 mgI/kg over 10 s)
Number of subjects: 98
Study 22043678 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture based on syndrome differentiation combined with pricking and cupping
Number of subjects: 86
Study 22043678 — intervention group
Group type: COMPARATOR
Intervention: Simple pricking and cupping
Number of subjects: 86
Study 18613931 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. dexmedetomidine 1‐4 mug.kg(‐1) bolus
Number of subjects: 45
Study 18613931 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation of an infusion of 1 mug.kg(‐1) over 10 min followed by an infusion of 0.7 mug.kg(‐1).h(‐1) for 50 min
Number of subjects: 45
Study 15760322 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly intramuscular methotrexate at 30 mg/m(2)
Number of subjects: 46
Study 15760322 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dactinomycin at 1.25 mg/m(2) every 2 weeks
Number of subjects: 46
Study 11896345 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-reduced RBCs
Number of subjects: 531
Study 11896345 — intervention group
Group type: COMPARATOR
Intervention: Unmodified RBCs
Number of subjects: 531
Study 10567783 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg o.d. for 7 days
Number of subjects: 40
Study 10567783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.d. for 7 days
Number of subjects: 40
Study 10567783 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 160 mg o.d. for 7 days
Number of subjects: 40
Study 10567783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7602635 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable staples
Number of subjects: 20
Study 7602635 — intervention group
Group type: COMPARATOR
Intervention: Metal staples
Number of subjects: 20
Study 2924604 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 percent oxygen
Number of subjects: 17
Study 2924604 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 17
Study 387068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride 40 mg by mouth daily
Number of subjects: 25
Study 387068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31186299 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 530
Study 31186299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 28108873 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 103
Study 28108873 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment hope
Number of subjects: 103
Study 28108873 — intervention group
Group type: COMPARATOR
Intervention: Adverse childhood experiences (ACEs)
Number of subjects: 103
Study 28108873 — intervention group
Group type: COMPARATOR
Intervention: Exposure to community violence (ECV)
Number of subjects: 103
Study 26292916 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive tutorials
Number of subjects: 99
Study 26292916 — intervention group
Group type: COMPARATOR
Intervention: Web resource (Control)
Number of subjects: 99
Study 23944300 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily plus ribavirin for 16 weeks (TID16W)
Number of subjects: 362
Study 23944300 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily plus ribavirin for 28 weeks (TID28W)
Number of subjects: 362
Study 23944300 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily plus ribavirin for 40 weeks (TID40W)
Number of subjects: 362
Study 23944300 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily and Deleobuvir 600 mg twice daily plus ribavirin for 28 weeks (BID28W)
Number of subjects: 362
Study 23944300 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily without ribavirin for 28 weeks (TID28W‐NR)
Number of subjects: 362
Study 23944300 — intervention group
Group type: COMPARATOR
Intervention: TID28W
Number of subjects: 362
Study 21740578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diamorphine
Number of subjects: 406
Study 21740578 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine
Number of subjects: 406
Study 18829025 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroactivation of oocytes (n = 1,640)
Number of subjects: 246
Study 18829025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electroactivation, n = 1,435)
Number of subjects: 246
Study 18829025 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 246
Study 16223550 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAT gene intron 9 SNP
Number of subjects: 1709
Study 16223550 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-site haplotype analysis of intron 9 SNP
Number of subjects: 1709
Study 16223550 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAT SNPs
Number of subjects: 1709
Study 15291378 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 10 mg/d
Number of subjects: 1547
Study 15291378 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg/d
Number of subjects: 1547
Study 11997274 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 11323
Study 11997274 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg/d)
Number of subjects: 11323
Study 11997274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both n-3 PUFAs and Vitamin E
Number of subjects: 11323
Study 11997274 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 11323
Study 9457003 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva sample request with incentives (lottery, pen)
Number of subjects: 2994
Study 9457003 — intervention group
Group type: COMPARATOR
Intervention: Control group (no saliva sample request)
Number of subjects: 2994
Study 9457003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery incentive
Number of subjects: 2994
Study 9457003 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen incentive
Number of subjects: 2994
Study 8903980 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 32
Study 2093382 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 60 mg per day
Number of subjects: 20
Study 342437 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 79
Study 342437 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 79
Study 29571969 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior myotomy
Number of subjects: 63
Study 29571969 — intervention group
Group type: COMPARATOR
Intervention: Posterior myotomy
Number of subjects: 63
Study 29571969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (anterior and posterior myotomy)
Number of subjects: 63
Study 26718414 — intervention group
Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 36
Study 26718414 — intervention group
Group type: COMPARATOR
Intervention: HF-DASH diet
Number of subjects: 36
Study 24020868 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed innocents with promised reward
Number of subjects: 100
Study 24020868 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilty participants with promised reward
Number of subjects: 100
Study 24020868 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed innocents without promised reward
Number of subjects: 100
Study 24020868 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilty participants without promised reward
Number of subjects: 100
Study 24020868 — intervention group
Group type: COMPARATOR
Intervention: Control group (uninformed innocents)
Number of subjects: 100
Study 24261811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vaccination with a minimum immunizing dose of BRSV (experiment 1)
Number of subjects: 84
Study 24261811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vaccination with a commercially available combination modified-live virus vaccine (experiments 2 and 3)
Number of subjects: 84
Study 24261811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vaccination (experiments 1, 2, and 3)
Number of subjects: 84
Study 20100020 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 385
Study 20100020 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 385
Study 20100020 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall AQLQ score
Number of subjects: 385
Study 20100020 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion domain of AQLQ
Number of subjects: 385
Study 20100020 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms domain of AQLQ
Number of subjects: 385
Study 20100020 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment AQLQ scores
Number of subjects: 385
Study 17551835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowman-Birk inhibitor concentrate (BBIC) for 12 weeks
Number of subjects: 0
Study 17551835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17242499 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone, 40 mg/day for 7 days
Number of subjects: 88
Study 17242499 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular triamcinolone LA, 40 mg/day for 3 days
Number of subjects: 88
Study 12540390 — intervention group
Group type: EXPERIMENTAL
Intervention: L. helveticus LBK‐16H fermented milk (150 mL/d)
Number of subjects: 39
Study 12540390 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 39
Study 10837004 — intervention group
Group type: EXPERIMENTAL
Intervention: Brassica vegetable diet
Number of subjects: 36
Study 10837004 — intervention group
Group type: EXPERIMENTAL
Intervention: Apiaceous vegetable diet
Number of subjects: 36
Study 10837004 — intervention group
Group type: COMPARATOR
Intervention: Basal (vegetable‐free) diet
Number of subjects: 36
Study 10837004 — intervention group
Group type: COMPARATOR
Intervention: Allium vegetable diet
Number of subjects: 36
Study 10837004 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT2 and xanthine oxidase activities
Number of subjects: 36
Study 8861533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily intravenously for 2-4 days followed by oral doses of 400 mg for up to 10 days
Number of subjects: 93
Study 8861533 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 400 mg twice daily intravenously for 2-4 days followed by oral doses of 2 x 500 mg for up to 10 days
Number of subjects: 93
Study 8861533 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 93
Study 1814749 — intervention group
Group type: EXPERIMENTAL
Intervention: Afferent tubular isoperistaltic ileal segment (20-cm length)
Number of subjects: 60
Study 1814749 — intervention group
Group type: COMPARATOR
Intervention: Antireflux nipple
Number of subjects: 60
Study 6366124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cyclophosphamide, vincristine and prednisone (CVP)
Number of subjects: 150
Study 6366124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cyclophosphamide, vincristine, procarbazine, and prednisone (C‐MOPP)
Number of subjects: 150
Study 6366124 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field, total lymphoid, or whole body irradiation, single alkylating agent chemotherapy
Number of subjects: 150
Study 6366124 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 150
Study 31310989 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training program
Number of subjects: 41
Study 28254107 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture to a myofascial trigger point (MTrP) in the upper trapezius
Number of subjects: 80
Study 28254107 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture to the MTrP in addition to relevant distal points
Number of subjects: 80
Study 28254107 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture to the relevant distal points only
Number of subjects: 80
Study 28254107 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment to both the MTrP and distal points using a deactivated acupuncture laser device
Number of subjects: 80
Study 25790807 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 55
Study 25790807 — intervention group
Group type: COMPARATOR
Intervention: Non-diuretic antihypertensive drugs
Number of subjects: 55
Study 25790807 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 23782796 — intervention group
Group type: EXPERIMENTAL
Intervention: mobiletype program (intervention group)
Number of subjects: 114
Study 23782796 — intervention group
Group type: COMPARATOR
Intervention: attention-comparison group (control)
Number of subjects: 114
Study 21752280 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT guided disease management + Telemonitoring (DM+TM)
Number of subjects: 220
Study 21752280 — intervention group
Group type: COMPARATOR
Intervention: ICT guided disease management (DM)
Number of subjects: 220
Study 19205490 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (proxymetacaine eye drops)
Number of subjects: 60
Study 19205490 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival anesthesia (2% xylocaine)
Number of subjects: 60
Study 19205490 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar anesthesia (2% xylocaine)
Number of subjects: 60
Study 16798995 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrodesis
Number of subjects: 31
Study 16798995 — intervention group
Group type: COMPARATOR
Intervention: Mayo resection
Number of subjects: 31
Study 15307520 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate and metoclopramide (1620 mg LAS + 10 mg MTC‐‐Migpriv)
Number of subjects: 98
Study 15307520 — intervention group
Group type: COMPARATOR
Intervention: Ergotamine plus caffeine (2 mg ERG + 200 mg CAF‐‐Coffecorn forte)
Number of subjects: 98
Study 10927062 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparoscopic ovarian drilling under local anesthesia and conscious sedation
Number of subjects: 62
Study 10927062 — intervention group
Group type: COMPARATOR
Intervention: Traditional ovarian drilling by laparoscopy under general anesthesia
Number of subjects: 62
Study 9709274 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening (invited women aged 40-49)
Number of subjects: 2468
Study 9709274 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening (invited women aged 50-74)
Number of subjects: 2468
Study 9709274 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly differentiated (grade 3) ductal carcinoma (invited women aged 40-49)
Number of subjects: 2468
Study 8310757 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A (two doses at day 0, one dose at day 21)
Number of subjects: 89
Study 8310757 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule B (one dose at days 0, 10 and 21)
Number of subjects: 89
Study 2874755 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 130
Study 2874755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 130
Study 2874755 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylactic therapy)
Number of subjects: 130
Study 2874755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (for termination of SVT)
Number of subjects: 130
Study 2874755 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (for termination of SVT)
Number of subjects: 130
Study 30946210 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg twice a day for 12 weeks)
Number of subjects: 72
Study 30946210 — intervention group
Group type: COMPARATOR
Intervention: Intranasal steroid (mometasone furoate nasal spray for 12 weeks)
Number of subjects: 72
Study 30946210 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Erythromycin and Intranasal steroid)
Number of subjects: 72
Study 28944218 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported comorbidities (including diabetes)
Number of subjects: 7540
Study 28944218 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported SMCs
Number of subjects: 7540
Study 25791214 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 8404
Study 25791214 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 8404
Study 23995774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine vaccine
Number of subjects: 114
Study 23995774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 21185661 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 33
Study 21185661 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI)
Number of subjects: 33
Study 21185661 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 33
Study 19272639 — intervention group
Group type: EXPERIMENTAL
Intervention: ERBB2 amplification defined as >2 copies of ERBB2/CEP17
Number of subjects: 133
Study 19272639 — intervention group
Group type: EXPERIMENTAL
Intervention: ERBB2 amplification defined as >4 copies of ERBB2/nuclei
Number of subjects: 133
Study 16572918 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg (test formulation)
Number of subjects: 24
Study 12511311 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 105
Study 12511311 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 105
Study 12511311 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 600 mg
Number of subjects: 105
Study 12174784 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat application (whole-body hot shower)
Number of subjects: 113
Study 12174784 — intervention group
Group type: COMPARATOR
Intervention: Parenteral analgesics or tranquillizers
Number of subjects: 113
Study 9850348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (100 micrograms twice daily)
Number of subjects: 23